For research use only. Not for therapeutic Use.
Etesevimab（Cat No.:I042243）is a monoclonal antibody developed to target and neutralize the spike protein of the SARS-CoV-2 virus, which causes COVID-19. It works by binding to the virus’s spike protein, preventing the virus from attaching to and entering human cells. Etesevimab has been studied for its potential use in combination with other monoclonal antibodies to treat COVID-19 patients, especially those with mild to moderate symptoms or at high risk for severe disease. Clinical trials have shown that it may help reduce viral load and improve patient outcomes when administered early in infection.
| Catalog Number | I042243 |
| CAS Number | 2423948-94-9 |
| Purity | ≥95% |
